NewslettersHepatic Cell News NorthSea Therapeutics Initiates Phase IIA Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) By lbeveridge - February 23, 2024 0 NorthSea Therapeutics B.V. announced the dosing of the first patient in its Phase IIa clinical trial of Orziloben in IFALD, an orphan liver disease affecting individuals on prolonged intravenous nutrition. [NorthSea Therapeutics B.V.] Press Release